The IP argument is rubbish. Publishing peer reviewed studies actually strengthens IP as it clearly establishes prior art.
And I could understand this strategy if RCE were going balls-to-the-wall getting P2 -> P3 trials ramped up and recruited.
But as we know they are just spinning up endless phase 1 trials that get abandoned, chasing new indications, collecting fat salaries with nothing to show from anything.
Ann: R327 added to WHO List of Antibacterial Products, page-11
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
-0.015(4.62%) |
Mkt cap ! $87.95M | |||
| Open | High | Low | Value | Volume |
| 32.5¢ | 33.0¢ | 30.5¢ | $50.49K | 160.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 3 | 22358 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 10059 | 2 |
View Market Depth
| Last trade - 15.06pm 18/06/2025 (20 minute delay) ? |
| RCE (ASX) Chart |